Ian Ganly is an Otolaryngologist in New York, New York. Ganly has been practicing medicine for over 34 years and is rated as an Elite expert by MediFind in the treatment of Oral Squamous Cell Carcinoma. He is also highly rated in 37 other conditions, according to our data. His top areas of expertise are Tongue Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Laryngectomy, and Tissue Biopsy. Ganly is currently accepting new patients.
Ezra Cohen is a Hematologist Oncology specialist and a Hematologist in La Jolla, California. Cohen has been practicing medicine for over 33 years and is rated as an Elite expert by MediFind in the treatment of Oral Squamous Cell Carcinoma. He is also highly rated in 16 other conditions, according to our data. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Oral Squamous Cell Carcinoma, and Squamous Cell Skin Carcinoma. Cohen is currently accepting new patients.
Luiz Kowalski practices in Sao Paulo, Brazil. Kowalski is rated as an Elite expert by MediFind in the treatment of Oral Squamous Cell Carcinoma. He is also highly rated in 28 other conditions, according to our data. His top areas of expertise are Oral Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Gland Tumors, Laryngectomy, and Endoscopy.
Summary: This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and ...
Summary: This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are four parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. In Part C, parti...